ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics ...
Silo Pharma, Inc. announced a service agreement with Resyca BV to conduct a drug-device study on its microchip-based nasal spray system for SPC-15, an intranasal treatment for PTSD. This study aims to ...
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery ...
Investigational New Drug (IND) submission to FDA on target forQ1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD CLIFFS ...
(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...
Thursday, Silo Pharma Inc (NASDAQ:SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The ...
A new economic impact study says South Plains College produces significant returns for the area's economy, students, businesses and taxpayers. The study reached three major conclusions. South Plains ...
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma (SILO), Inc. (“the Company”), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results